---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-052248"
form_type: "8-K"
ticker: "BFRG"
cik: "0001829247"
company_name: "BullFrog AI Holdings, Inc."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:06:14.305590+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bullfrog AI CEO highlights AI platform advances, LIBD collaboration, BF-114 progress, $8.83M raised in 2024

## Summary
- bfLEAP platform enhanced with generative and causal AI exclusively licensed from Johns Hopkins APL, enabling explainable AI for target discovery and drug repositioning.
- LIBD collaboration identified novel drug targets for schizophrenia, bipolar disorder, and major depressive disorder; advanced pharma discussions underway.
- BF-114 demonstrated potential in obesity, MASLD, and HCC; published in Cell Reports. Liver disease market projected to exceed $36.5B by 2030.
- Raised $8.83M from two equity offerings in 2024, bolstering cash position for growth initiatives and working capital.
- Strengthened IP with Australian patent for BF-223 (oncology, glioblastoma); added Dr. Chittenden as CSO and Dr. Baldoni to SAB.

## SEC filing metadata
- accession: 0001493152-24-052248
- form_type: 8-K
- ticker: BFRG
- cik: 0001829247
- company_name: BullFrog AI Holdings, Inc.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829247/000149315224052248/0001493152-24-052248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829247/000149315224052248/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-052248
- JSON: https://secwatch.observer/filing/0001493152-24-052248.json
- Plain text: https://secwatch.observer/filing/0001493152-24-052248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.